Peregrine Capital Management LLC Acquires 54,100 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Peregrine Capital Management LLC lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 18.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 352,205 shares of the medical equipment provider's stock after acquiring an additional 54,100 shares during the period. Peregrine Capital Management LLC owned approximately 0.76% of BioLife Solutions worth $9,143,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter worth $28,000. Quest Partners LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter worth $57,000. Summit Global Investments bought a new stake in shares of BioLife Solutions during the 3rd quarter worth $228,000. Intech Investment Management LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter worth $255,000. Finally, Stifel Financial Corp lifted its holdings in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after acquiring an additional 670 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

Insider Buying and Selling at BioLife Solutions

In related news, CFO Troy Wichterman sold 987 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares in the company, valued at $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Aby J. Mathew sold 7,604 shares of the business's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. This represents a 2.68 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,678 shares of company stock worth $317,990. 2.20% of the stock is currently owned by company insiders.

BioLife Solutions Trading Down 3.1 %

Shares of BLFS stock traded down $0.84 during mid-day trading on Friday, reaching $26.67. The stock had a trading volume of 259,865 shares, compared to its average volume of 238,070. The stock's 50-day moving average price is $26.93 and its two-hundred day moving average price is $25.47. BioLife Solutions, Inc. has a 52-week low of $14.50 and a 52-week high of $29.55. The firm has a market capitalization of $1.24 billion, a PE ratio of -25.16 and a beta of 1.91. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. TD Cowen boosted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. KeyCorp boosted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. HC Wainwright lowered their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research note on Monday, November 18th. Benchmark reissued a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, Northland Securities boosted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat, BioLife Solutions currently has an average rating of "Moderate Buy" and an average target price of $29.43.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.